Contact DMCA Privacy

Robuta

Sponsor of the Day: Jerkmate
https://recovercovid.org/publications/design-and-rationale-recover-autonomic-randomized-platform-trial-evaluating Design and rationale of RECOVER-AUTONOMIC: a randomized platform trial evaluating interventions for... Background: Post‑acute sequelae of SARS‑CoV‑2 infection (Long COVID) affect a substantial proportion of individuals, and among the many reported symptom recover autonomicplatform trialdesignrationalerandomized https://www.nature.com/articles/s41598-021-88509-9?error=cookies_not_supported&code=e1679150-9bef-4c2f-8d74-9ec8068d0bc8 An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine... Apr 27, 2021 - Despite several studies designed to evaluate the efficacy of chloroquine and hydroxychloroquine in the treatment of coronavirus disease 2019 (COVID-19), there... open label randomizedcontrolled trial evaluatingefficacychloroquine https://www.merck.com/news/merck-announces-initiation-of-pivotal-phase-2b-3-trial-evaluating-mk-8748-tiespectus-an-investigational-bispecific-tie2-agonist-vegf-inhibitor-for-the-treatment-of-neovascular-age-related-macular/ Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an... Apr 6, 2026 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also... announces initiationpivotal phase2b 3trial evaluatingmerck https://www.nature.com/articles/s41598-021-88509-9?error=cookies_not_supported&code=cd0d4829-1784-4a9a-b149-1ed07df0a948 An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine... Apr 27, 2021 - Despite several studies designed to evaluate the efficacy of chloroquine and hydroxychloroquine in the treatment of coronavirus disease 2019 (COVID-19), there... open label randomizedcontrolled trial evaluatingefficacychloroquine https://www.nature.com/articles/s41598-021-88509-9?fromPaywallRec=false&error=cookies_not_supported&code=5927649b-1b27-41ab-888a-504ca448b374 An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine... Apr 27, 2021 - Despite several studies designed to evaluate the efficacy of chloroquine and hydroxychloroquine in the treatment of coronavirus disease 2019 (COVID-19), there... open label randomizedcontrolled trial evaluatingefficacychloroquine https://www.cancernetwork.com/view/new-frontiers-in-adjuvant-care-evaluating-elacestrant-in-the-elegant-trial New Frontiers in Adjuvant Care: Evaluating Elacestrant in the ELEGANT Trial | CancerNetwork Apr 24, 2026 - Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer. new frontiersadjuvantcareevaluatingelegant